215 related articles for article (PubMed ID: 19141119)
1. Conventional cytogenetics in myelofibrosis: literature review and discussion.
Hussein K; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
[TBL] [Abstract][Full Text] [Related]
2. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
Dingli D; Schwager SM; Mesa RA; Li CY; Dewald GW; Tefferi A
Cancer; 2006 May; 106(9):1985-9. PubMed ID: 16568439
[TBL] [Abstract][Full Text] [Related]
3. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
[TBL] [Abstract][Full Text] [Related]
4. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
Hidaka T; Shide K; Shimoda H; Kameda T; Toyama K; Katayose K; Kubuki Y; Nagata K; Takenaka K; Akashi K; Okamura T; Niho Y; Mizoguchi H; Omine M; Ozawa K; Harada M; Shimoda K
Eur J Haematol; 2009 Oct; 83(4):328-33. PubMed ID: 19549278
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia.
Strasser-Weippl K; Steurer M; Kees M; Augustin F; Tzankov A; Dirnhofer S; Fiegl M; Simonitsch-Klupp I; Gisslinger H; Zojer N; Ludwig H
Cancer; 2006 Dec; 107(12):2801-6. PubMed ID: 17103442
[TBL] [Abstract][Full Text] [Related]
6. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients.
Djordjevic V; Dencic-Fekete M; Jovanovic J; Bizic S; Jankovic G; Bogdanovic A; Cemerikic-Martinovic V; Gotic M
Cancer Genet Cytogenet; 2007 Feb; 173(1):57-62. PubMed ID: 17284371
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations.
Caramazza D; Hussein K; Siragusa S; Pardanani A; Knudson RA; Ketterling RP; Tefferi A
Eur J Haematol; 2010 Mar; 84(3):191-200. PubMed ID: 20002154
[TBL] [Abstract][Full Text] [Related]
9. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
Swolin B; Rödjer S; Westin J
Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
[TBL] [Abstract][Full Text] [Related]
10. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.
Tefferi A; Dingli D; Li CY; Dewald GW
Cancer; 2005 Oct; 104(8):1656-60. PubMed ID: 16104040
[TBL] [Abstract][Full Text] [Related]
11. Karyotype and molecular cytogenetic studies in polycythemia vera.
Andrieux JL; Demory JL
Curr Hematol Rep; 2005 May; 4(3):224-9. PubMed ID: 15865876
[TBL] [Abstract][Full Text] [Related]
12. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
Gregory SA; Mesa RA; Hoffman R; Shammo JM
Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
[TBL] [Abstract][Full Text] [Related]
14. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
15. The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis.
Miller JB; Testa JR; Lindgren V; Rowley JD
Cancer; 1985 Feb; 55(3):582-91. PubMed ID: 3965109
[TBL] [Abstract][Full Text] [Related]
16. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
17. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.
Tefferi A; Nicolosi M; Mudireddy M; Lasho TL; Gangat N; Begna KH; Hanson CA; Ketterling RP; Pardanani A
Leukemia; 2018 May; 32(5):1189-1199. PubMed ID: 29472717
[TBL] [Abstract][Full Text] [Related]
18. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.
Caramazza D; Begna KH; Gangat N; Vaidya R; Siragusa S; Van Dyke DL; Hanson C; Pardanani A; Tefferi A
Leukemia; 2011 Jan; 25(1):82-8. PubMed ID: 20944670
[TBL] [Abstract][Full Text] [Related]
19. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.
Hsiao HH; Ito Y; Sashida G; Ohyashiki JH; Ohyashiki K
Leuk Res; 2005 Nov; 29(11):1247-52. PubMed ID: 16164981
[TBL] [Abstract][Full Text] [Related]
20. Myeloproliferative disorders.
Bench AJ; Cross NC; Huntly BJ; Nacheva EP; Green AR
Best Pract Res Clin Haematol; 2001 Sep; 14(3):531-51. PubMed ID: 11640868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
